Study identifier:D6702C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression
Treatment resistant Major Depressive Disorder
Phase 2
No
AZD6765, Placebo to AZD6765
All
22
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2014 by AstraZeneca
AstraZeneca
NIMH
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD6765 (150 mg) / Placebo Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period. | Drug: AZD6765 Single IV infusion of 150 mg AZD6765. |
Placebo Comparator: Placebo / AZD6765 (150 mg) Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period. | Drug: Placebo to AZD6765 Single IV infusion of Placebo to AZD6765 |